What is the FLIPI Score for Follicular Lymphoma?

The Follicular Lymphoma International Prognostic Index (FLIPI) is a standard tool oncologists use to predict how your follicular lymphoma might behave over time ^[1]. When you are first diagnosed, your care team uses this scoring system to estimate your long-term outlook (prognosis) ^[2].

While the FLIPI score helps predict the course of your disease, it is not usually the main factor your doctor uses to decide when to start treatment ^[3][4].

The Five FLIPI Criteria

The FLIPI score is calculated by looking at five specific clinical and laboratory factors at the time of your diagnosis ^[5][6]. You get one point for each factor that is present. Some doctors use the acronym NoLASH to remember these:

• N - Nodal Areas: Do you have lymphoma in more than 4 distinct lymph node areas? This does not mean individual lymph nodes. Oncologists group lymph nodes into “areas” or regions—such as the cervical (neck), axillary (armpits), or inguinal (groin) regions on each side of the body ^[7].
• L - LDH (Lactate Dehydrogenase): Is your serum LDH level higher than normal? LDH is an enzyme found in many tissues; elevated blood levels can indicate rapid cell turnover, which is often seen in lymphoma ^[5].
• A - Age: Are you over 60 years old? (1 point)
• S - Stage: Is your lymphoma Ann Arbor Stage III or IV? This means the lymphoma is found in lymph nodes on both sides of the diaphragm, or it has spread to organs outside the lymphatic system ^[5].
• H - Hemoglobin: Is your hemoglobin level below 12 g/dL? Hemoglobin is the protein in your red blood cells that carries oxygen, and a low level indicates anemia ^[5].

Understanding Your Risk Category and Survival Statistics

By adding up your points (from 0 to 5), your oncologist places you into one of three risk categories ^[5]:

• Low Risk (0 or 1 point): The disease is expected to be slow-growing with a highly favorable long-term outlook.
• Intermediate Risk (2 points): The disease has a moderate risk of progression.
• High (or Poor) Risk (3, 4, or 5 points): The disease has a higher chance of progressing more quickly or returning after treatment ^[7][8].

It is incredibly important to view survival statistics in the right context. The original FLIPI study was published in 2004, before the widespread use of modern targeted immune therapies like rituximab ^[5]. That early study reported a 10-year survival rate of around 71% for low-risk patients and 36% for high-risk patients ^[5].

These historical numbers are outdated. Today, thanks to modern immunochemotherapy (treatments combining immune therapy and chemotherapy), people with follicular lymphoma are living much longer, and average survival is often measured in decades ^[9][10]. Even if you are in the high-risk category, follicular lymphoma remains highly treatable ^[2].

Note: You may also see newer scoring models on your chart, such as FLIPI-2 or PRIMA-PI. These updated models look at slightly different factors (like beta-2 microglobulin) to further refine predictions for patients receiving modern therapies ^[1][11].

How FLIPI Impacts Treatment Timing

It is crucial to understand the difference between prognosis (what the FLIPI score measures) and tumor burden (which dictates when you need treatment) ^[4].

Many patients assume a high FLIPI score means they must start treatment immediately. This is not always the case ^[3]. Oncologists generally use a different set of criteria (such as the GELF criteria) to evaluate your “tumor burden”—meaning how much the lymphoma is actively affecting your body ^[12]. GELF criteria look for signs that the lymphoma is causing immediate problems, such as bulky tumors (e.g., a tumor larger than 7 centimeters), fluid buildup, or significant symptoms like severe fatigue or drenching night sweats ^[13][14].

If your tumor burden is low and you have no symptoms, your doctor might still recommend a “watch and wait” (active surveillance) approach, even if your FLIPI score is intermediate or high ^[3][15]. Studies show that starting systemic therapy early for asymptomatic patients does not improve how long they live compared to watching and waiting until symptoms appear ^[15].

The FLIPI score helps your doctor understand the overarching biology of your lymphoma, allowing them to better tailor your long-term monitoring and select the appropriate intensity of treatments once therapy is actually needed ^[16][17].